H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales

Alnylam posted Q1 2026 total net product revenue of $1.036 billion, up 121% year over year and slightly above FactSet consensus of $1.032 billion, while the transthyretin franchise generated $910.4 million, up 153%. H.C. Wainwright reaffirmed a Buy rating and $510 price target, and the company held its full-year 2026 product revenue guidance at $4.9 billion to $5.3 billion. The quarter marks Alnylam's first time above $1 billion in quarterly net product revenue, supporting a positive read-through for the stock.

Analysis

ALNY’s beat is not just a quarterly print; it materially de-risks the platform narrative by showing that the TTR franchise can still compound at scale without obvious saturation. The second-order implication is that the market may be underestimating operating leverage: once a biologic franchise reaches this revenue base, incremental growth can translate into outsized free-cash-flow expansion because manufacturing, SG&A, and commercial infrastructure should grow slower than sales. That argues for the equity to remain bid on any volatility, even if absolute valuation screens rich.

The competitive read-through is more interesting than the headline. If ALNY is approaching parity in new starts versus the incumbent in the main cardiomyopathy channel, the battleground shifts from pure efficacy to persistence, payer friction, and physician habit formation. That tends to favor the company with stronger field execution and broader label optionality, while pressuring competitors that rely on legacy brand inertia. It also raises the stakes for any negative formulary or adherence data: small share changes at this penetration rate can move revenue by hundreds of millions annually.

The main risk is that the stock is now pricing a lot of near-perfect execution into multiple future catalysts. Zilebesiran is the cleanest swing factor, but it is still a binary, multi-month readout with limited visibility; if that trial disappoints, the market may quickly re-rate ALNY back to a “single-franchise story” despite the current momentum. Near term, the bigger trap is multiple compression: consensus may keep raising estimates, but if the growth inflects from ‘surprise’ to ‘expected,’ the stock can stall even while fundamentals remain strong.

The contrarian view is that the best risk/reward may no longer be in chasing outright long exposure after a strong rerate; instead, the opportunity is in expressing bullish fundamentals versus a skeptical market with defined downside. Pfizer is the obvious loser on relative momentum if share gains keep compounding, but this is more about lost growth optionality than immediate earnings damage. The real tell over the next 1-2 quarters will be whether new-start share gains translate into durable persistence and net price stability, not just top-line acceleration.

Key Decisions for Investors

• Maintain long ALNY, but reduce size on strength and use pullbacks to add; best held as a 3-6 month momentum-plus-fundamentals position with upside if the market starts capitalizing TTR FCF at a higher multiple.
• Buy ALNY call spreads into the next catalyst window for ZENITH readouts; favorable if the market is underpricing optionality, with defined downside versus common equity.
• Pair trade: long ALNY / short PFE for 2-3 months as a relative-value expression of share gains and pipeline optionality versus a more mature franchise; risk is short-leg weakness in PFE not keeping pace with ALNY upside.
• If ALNY rallies another 10-15% before the next data event, consider hedging with out-of-the-money puts or reducing gross, since multiple compression risk rises once the ‘beat-and-raise’ narrative becomes fully consensus.
• Monitor payer and persistence metrics closely; if net retention or formulary data soften, cut quickly, because the bull case is levered to durable conversion, not just one quarter of outsized growth.